Omeros' (OMER) Hold Rating Reiterated at Needham & Company LLC

Key Points

• Omeros Corporation's stock received a "hold" rating from Needham & Company LLC, amidst mixed analyst opinions with price targets ranging from $20.00 to $45.00.
• The company reported an earnings per share (EPS) of ($0.53) for the last quarter, exceeding expectations of ($0.55), with substantial revenue of $28.60 million.
• Recent institutional trading indicates a significant increase in holdings, including a substantial 14,486.3% increase by GAMMA Investing LLC in the first quarter.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "hold" rating reiterated by stock analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

A number of other analysts have also recently commented on OMER. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Omeros in a research note on Wednesday, October 8th. WBB Securities restated a "strong-buy" rating and set a $45.00 price objective on shares of Omeros in a research note on Wednesday. D. Boral Capital reiterated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Wednesday. HC Wainwright raised their target price on shares of Omeros from $9.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $27.50.

Omeros Price Performance

Shares of OMER traded up $6.88 on Wednesday, hitting $10.98. The company's stock had a trading volume of 106,309,025 shares, compared to its average volume of 1,420,737. The company has a market capitalization of $747.09 million, a PE ratio of -5.07 and a beta of 2.32. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The company has a 50 day moving average price of $4.24 and a 200 day moving average price of $4.50.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. On average, equities analysts forecast that Omeros will post -3.09 EPS for the current year.

Institutional Trading of Omeros

A number of institutional investors have recently modified their holdings of OMER. GAMMA Investing LLC increased its holdings in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Omeros in the 1st quarter worth about $579,000. Brighton Jones LLC lifted its position in shares of Omeros by 11.3% in the 1st quarter. Brighton Jones LLC now owns 30,714 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 3,125 shares during the period. Sowell Financial Services LLC purchased a new stake in shares of Omeros in the 1st quarter worth about $88,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Omeros by 2.2% in the 1st quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock worth $1,242,000 after purchasing an additional 3,321 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.